brca my treatment
514 articles
Progress in BRCA-Related Cancers Highlighted By the Basser Center
The Basser Center for BRCA hosted a panel discussion of the latest breakthroughs and discoveries for BRCA-related cancers.
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
New NCCN Guidelines Stress Genetic Testing For All Pancreatic Cancer Patients
Genetics impact your treatment for pancreatic cancer. Dr. Sapna Syngal discusses the recommendation of genetic testing for all pancreatic cancer patients.
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
My BRCA2 Mutation Turned Out to Be Both the Curse and the Cure
Sharon Seibel knew she had the BRCA2 mutation but was unaware of the link to pancreatic cancer. Her chemotherapy was one for BRCA carriers.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Understanding Family History Makes a Difference in Treatment Options
Elizabeth Pršić describes her mother Andrea’s pancreatic cancer treatment. Andrea has the BRCA2 mutation, which helps determine the plan.